The Food and Drug Administration has reiterated a warning after approving a new antidepressant in a class known as selective serotonin reuptake inhibitors (SSRIs). Vilazodone hydrochloride, sold as Viibryd, will carry a “blackbox” side effects warning similar to other SSRIs, including Zoloft and Paxil.
The drug has also been linked to a possibility of kidney failure and memory loss. The FDA placed Viibryd in Pregnancy Category C, meaning the drug could increase the risk of severe birth defects.
Viibryd’s warning comes as no surprise, as Zoloft and other SSRIs have been linked to an increased risk of severe birth defects, including setpal defects and other congenital birth defects. According to a 2006 study in the New England Journal of Medicine, women who use SSRI’s during pregnancy are up to six times more likely to give birth to a child with persistent pulmonary hypertension of the newborn (PPHN).